Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.

BACKGROUND Triple-negative (ie, estrogen receptor [ER], progesterone receptor, and HER2 negative) breast cancer occurs disproportionately among African American women compared with white women and is associated with a worse prognosis than ER-positive (ER+) breast cancer. Hormonally mediated risk factors may be differentially related to risk of triple-negative and ER+ breast cancers. METHODS Using data from 155,723 women enrolled in the Women's Health Initiative, we assessed associations between reproductive and menstrual history, breastfeeding, oral contraceptive use, and subtype-specific breast cancer risk. We used Cox regression to evaluate associations with triple-negative (N = 307) and ER+ (N = 2610) breast cancers and used partial likelihood methods to test for differences in subtype-specific hazard ratios (HRs). RESULTS Reproductive history was differentially associated with risk of triple-negative and ER+ breast cancers. Nulliparity was associated with decreased risk of triple-negative breast cancer (HR = 0.61, 95% confidence interval [CI] = 0.37 to 0.97) but increased risk of ER+ breast cancer (HR = 1.35, 95% CI = 1.20 to 1.52). Age-adjusted absolute rates of triple-negative breast cancer were 2.71 and 1.54 per 10,000 person-years in parous and nulliparous women, respectively; by comparison, rates of ER+ breast cancer were 21.10 and 28.16 per 10,000 person-years in the same two groups. Among parous women, the number of births was positively associated with risk of triple-negative disease (HR for three births or more vs one birth = 1.46, 95% CI = 0.82 to 2.63) and inversely associated with risk of ER+ disease (HR = 0.88, 95% CI = 0.74 to 1.04). Ages at menarche and menopause were modestly associated with risk of ER+ but not triple-negative breast cancer; breastfeeding and oral contraceptive use were not associated with either subtype. CONCLUSION The association between parity and breast cancer risk differs appreciably for ER+ and triple-negative breast cancers. These findings require further confirmation because the biological mechanisms underlying these differences are uncertain.

[1]  B. Strom,et al.  Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. , 2010, Cancer research.

[2]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[3]  F. Clavel-Chapelon,et al.  Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women , 2002, British Journal of Cancer.

[4]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[5]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[6]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[7]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[8]  M. García-Closas,et al.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  L. Lipworth,et al.  History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. , 2000, Journal of the National Cancer Institute.

[10]  R C Millikan,et al.  Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. , 2000, American journal of epidemiology.

[11]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[12]  M. García-Closas,et al.  Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[13]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[14]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[15]  Garnet L Anderson,et al.  The Women's Health Initiative recruitment methods and results. , 2003, Annals of epidemiology.

[16]  J. Cerhan,et al.  Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[18]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[19]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[20]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[21]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[22]  P. Porter,et al.  Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer , 2009, Cancer.

[23]  D. Levine,et al.  44th Annual Meeting of the American Society of Clinical Oncology. , 2008, Gynecologic oncology.

[24]  R. Coates,et al.  The epidemiology of triple-negative breast cancer, including race , 2009, Cancer Causes & Control.

[25]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[26]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[27]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[29]  R. Coates,et al.  Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA , 2008, Breast Cancer Research and Treatment.

[30]  F. Jin,et al.  A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China , 2010, Medical oncology.

[31]  B. Strom,et al.  Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology , 2005, British Journal of Cancer.

[32]  G Leclercq,et al.  Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. , 2004, Endocrine-related cancer.

[33]  P. Hall,et al.  Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women , 2006, Cancer Epidemiology Biomarkers & Prevention.

[34]  L. Brinton,et al.  Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.

[35]  A. Kapke,et al.  Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women , 2008, Breast Cancer Research and Treatment.